Cell Death Induction Mechanism of Non-small Cell Lung Cancer Cell Line, NCI-H1703 by Docetaxel.
- Author:
Hyeon Cheol HA
1
;
Yeong Dae KIM
;
Seung Hwan SONG
;
Chin Su PARK
;
Jong Won KIM
Author Information
1. Department of Thoracic and Cardiovascular Surgery, College of Medicine, Pusan National University, Korea. domini@pnu.edu
- Publication Type:Original Article
- Keywords:
Carcinoma, non-small cell, lung;
Neoplasm biology;
Cell death
- MeSH:
Blotting, Western;
Carcinoma, Non-Small-Cell Lung*;
Caspase 3;
Caspase 9;
Cell Death*;
Cell Line*;
Flow Cytometry;
G2 Phase;
Lung Neoplasms;
Microscopy, Fluorescence;
S Phase
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
2006;39(9):668-673
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Docetaxel has been effectively used as an anti-cancer chemotherapuetic agent for various tumor treatments including lung cancer. However, the cell death induction mechanism(s) involved with docetaxel treatment in lung cancer cells has not been known yet. MATERIAL AND METHOD: In the present study, the cellular and biochemical changes of NCI-H1703 cells (non-small cell lung cancer cell line, p53-mutant) after docetaxel treatment have been monitored by flow cytometry, fluorescence microscopy and western blot. RESULT: Docetaxel treatment significantly resulted in decrease of S phase as well as increase of G2 phase, and consequently evoked an increase of cell death in NCI-H1703 cells. After docetaxel exposure the activations of caspase-3 and caspase-9 were detected. CONCLUSION: Take together, it is suggested that the docetaxel induces NCI-H1703 cell death by caspase-9 and caspase-3 dependent mitochondrial apoptotic pathway.
